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Abstract
Background: Microarray data analysts commonly filter out genes based on a number of ad hoc
criteria prior to any high-level statistical analysis. Such ad hoc approaches could lead to conflicting
conclusions with no clear guidance as to which method is most likely to be reproducible.
Furthermore, the number of tests performed with concomitant inflation in type I error also plagues
the statistical analysis of microarray data, since the number of tested quantities in a study
significantly affects the family-wise error rate. It would, therefore, be very useful to develop and
adopt strategies that allow quantification of the quality of each probeset, to filter out or give little
credence to low-quality or unexpressed probesets, and to incorporate these strategies into gene
selection within a multiple testing framework.
Results: We have proposed a unified scheme for filtering and gene selection. For Affymetrix gene
expression microarrays, we developed new methods for measuring the reliability of a particular
probeset in a single array, and we used these to develop measures for a set of arrays. These
measures are then used as weights in standard t-statistic calculations, and are incorporated into the
multiple testing procedures. We demonstrated the advantages of our methods using simulated
data, publicly available spiked-in data as well as data comparing normal muscle to muscle from
patients with Duchenne muscular dystrophy (DMD), in which a set of truly differentially expressed
genes is known.
Conclusion: Our quality measures provide convenient ways to search for individual genes of high
quality. The quality weighting strategies we proposed for testing differential gene expression have
demonstrable improvement on the traditional filtering methods, the standard t-statistic and a
regularized t-statistic in Affymetrix data analysis.
Background
Affymetrix GeneChip™ microarrays are used to measure
gene expression for thousands of transcripts simultane-
ously. Each transcript is measured by 11–20 probesets,
where a probeset consists of two almost identical
sequences of length 25 bp. One member of the pair is the
perfect match (PM) probe, where the sequence is the exact
complement of a section of the mRNA. The other member
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of the pair, the mismatch probe (MM), is identical to the
PM probe except for the nucleotide in 13th position and is
intended to measure and control for non-specific binding
signals. The accuracy and sensitivity of the measurement
for any one gene or EST depends on the uniqueness and
the binding properties of the probes.
It is well known that most probesets perform consistently
and reliably, in that similar estimates of expression are
obtained from two replicates of an experiment. However,
in many cases, the signals from a probeset can be hard to
interpret. There may be substantial variability across the
probesets in the estimated level of expression, or in the
PM-MM differences. PM signals can be smaller than MM
signals suggesting high levels of non-specific binding. It is
also well known that a large proportion of the genes are
expressed in only a few tissues or at a particular develop-
mental stage, and hence many of the genes are not
expected to have a measurable transcribed product. Su et
al. [1] have estimated that in most cases, only 30–40% of
the genome will be expressed in any one tissue. In such sit-
uations, the probesets give measurements for PM and MM
that fluctuate near the lower detectable limit.
The latest release for the Affymetrix GeneChip Expression
Analysis Platform, GeneChip Human Genome U133 Plus
2.0 Array [2], provides comprehensive coverage of the
transcribed human genome on a single array. The array
includes more than 54,000 probesets with 38,500 well-
characterized human genes. When analyzing such a large
number of genes, the adjustment of significance levels
through multiple testing procedures such as the Bonfer-
roni method [3], or Benjamini and Hochberg [4], may be
dramatic enough to make it very difficult to identify differ-
entially expressed genes. However, if we knew which tran-
scripts were either not expressed in the tissue under study,
or were measured unreliably due to poor probe specificity,
we could exclude these transcripts from the analysis and
pay a smaller penalty for multiple testing.
In 2001, Affymetrix produced a new algorithm for sum-
marizing the results of a probeset, and the algorithm
includes a detection p-value, which represents the proba-
bility that the probeset (gene) expression is above zero
(i.e., turned on), and measured reliably and consistently
across the probe. In addition, "Present/Marginal/Absent"
(P/M/A) calls for each transcript are based on the detec-
tion p-value together with thresholds that can be altered
by the user [5]. The calls are often used as filters to keep
genes whose transcripts are detectable in a particular
experiment [6-8], and this filtering concept has been inte-
grated into some software such as dChip [9,10]. For exam-
ple, Blalock, et al. [7] removed a probeset from further
statistical analysis if there were > = 60% absent calls, for
that probeset, in at least one treatment group. However,
the stringency of the filtering procedure can strongly affect
downstream analyses and the final results. Too much fil-
tering may exclude some important genes, whereas too lit-
tle filtering will reduce power by increasing the number of
tests performed. Moreover, it is possible that the statistical
error introduced by imperfect filtering criteria makes the
overall error worse. Pounds and Cheng [11] recently
argued that it is better to define gene filters based on the
detection p-value than on the calls, so that more of the
available information about probeset reliability can be
used. They developed two pooled filters for each probeset
based on detection p-values.
An alternative strategy to filtering is to treat probe-specific
variability as a quality index to measure the reliability of
each probeset. Although many summaries of Affymetrix
GeneChip expression have been proposed (e.g. MAS5 [5],
dChip [9,10], RMA [12], PLIER [13] and gcRMA [14]),
there have been few studies on quality measures for
Affymetrix GeneChip expression data. In previous studies,
typically, once a filtering decision was made, the esti-
mated intensities of each probeset were considered to be
equally well measured, so that probesets with highly vari-
able signals were considered as reliable as probesets with
inconsistent signals. However, probesets that detect tran-
scripts expressed at a very high level would be expected to
show a more robust signal with greater quality than
probesets that are performing poorly or detecting very low
level transcripts.
Seo et al. [15] used the detection p-values to develop
weighted Pearson correlations between expression meas-
urements from two different arrays. The weight was
defined to be a function of the two detection p-values for
each probeset. They incorporated these weighted correla-
tions into unsupervised clustering analysis, with the goal
of choosing the best algorithm for summarizing across the
probesets.
In this study, we focus on the problem of testing for differ-
ential expression between groups of arrays, while adjust-
ing for multiple testing in a weighted framework. We
redefine some of the widely used filtering methods [6-9]
and also propose some new methods for measuring the
quality of a particular probeset in a single array, in an
experimental group of arrays, and in an entire study.
These measures are then used as weights in t-statistic cal-
culations, and are incorporated into the multiple testing
procedures. We applied these methods to a dataset of
expression in muscle tissue [16], Choe's spiked-in data
[17] and simulated data. One of our quality measures for
an experimental group is based on the measure developed
very recently by Pounds and Cheng [11]; however, we go
further in combining measures across groups, and in dis-BMC Genomics 2006, 7:33 http://www.biomedcentral.com/1471-2164/7/33
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cussing the usefulness of these measures when testing for
differential gene expression.
Results
Test statistics and quality measures
We propose a weighting paradigm for including quality
measures into analysis when testing for differential
expression. Suppose that an unweighted test statistic for
gene g is represented by tg, and that the quality measure is
called Qg. We propose to evaluate the significance of gene
g using the weighted test statistic   = tgQg. The impact of
the weighting on the pattern of results, across all genes, is
then taken into account when calculating significance
adjusted for multiple testing, or when estimating the false
discovery rate. Conceptually, giving a low weight, Qg≈0, to
a particular gene can be thought of as excluding that gene
from consideration. Therefore, our modifications to mul-
tiple-testing methods are based on adjusting the number
of genes tested, based on the quality measures.
Measure Qg must represent a summary across treatment
groups w ∈ {1 ...W}. We propose
where   is a treatment-group specific measure of qual-
ity. By using the maximum value across groups in equa-
tion (1), a gene that is clearly expressed in one or more
groups will be considered as a gene measured with high
quality.
We examine the performance of several choices for the
group-specific quality measure  . In particular,   =
1.0 leads, after using equation (1), to a measure   that
is, in fact, no quality filtering: all genes are included in the
analysis at full weight. The common practice of analyzing
only genes with present calls can be based on {  = 1.0
when all arrays in group w have present calls, and   = 0
otherwise}. We will denote this as  .
Instead of using the Affymetrix present/absent calls, more
sensitivity can be gained by basing   on the actual
detection p-values, qgiw for gene g, array i, and group w.
Since a highly-expressed gene corresponds to a small
detection p-value, we propose   = 1 -  , where 
tg
*
QR gw W g
w = () ∈ max [ ], {} 1 1 …
Rg
w
Rg
w Rg
w
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Table 1: Test statistics and quality measures. For the quality-based tests, the summarized quality measure, across treatment groups, is 
defined by Qg = maxw∈{1...W}  .
Quality Measures Array specific measure
Group-specific measure 
Notes
1.0 1.0 No filtering
All arrays must have present call 
to be included
qgiw = detection p-value nw is the number of arrays in group 
w
qgiw = detection p-value
 for sensitivity 
parameter ν
qgiw = detection p-value
qgiw = detection p-value N/A Weighted means   and 
weighted standard deviations Sgw
N/A N/A Local pooled error test [18]
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is the mean detection p-value for group w, leading to a
quality measure that we call  . The mean may not
give enough weight to small p-values, therefore we also
investigated two measures that are based on parametric
model assumptions for the distribution of detection p-val-
ues. Firstly, we assumed that -log(qgiw) follow an exponen-
tial distribution with group-specific mean λqw. Under this
distribution, the probability that the detection p-values
will be smaller than a threshold ν  can be written as
, with corresponding   following
from equation (1).
Although, under the null hypothesis of no signal, the
detection p-values can be expected to follow a uniform
distribution (so that -log(q) is exponential with mean
1.0), when there is a signal, the p-value distribution is bet-
ter described by the two-parameter Beta distribution.
However, detection p-values are based on rank tests and
there is often little variability in the p-values across arrays
for highly expressed genes. This leads to difficulties in esti-
mating two parameters. Pounds and Cheng [11] proposed
a one-parameter Beta distribution for detection p-values,
so that  , and we
incorporate this measure into our corresponding across-
group quality measure  .
For comparison, two very different test statistics were also
used: (1) Weights based on the detection p-values were
incorporated directly in the calculation of group-specific
means and standard deviations – we refer to this test sta-
tistic as   to follow our naming convention, although
no quality measure is defined; (2) In addition, we used
the local pooled error (LPE) test [18], which is based on
pooling errors within genes and between replicate arrays
for genes in which expression values are similar. This test
is referred to as  . Unweighted multiple testing cor-
rections were implemented for these two tests. Table 1
summarizes the different test statistics and quality meas-
ures used in the paper.
Analysis of simulated data
The performance of our proposed methods was evaluated
using simulated probe level data generated from a model
incorporating probe level effects, optical noise, and non-
specific binding, as well as true signals [14]. We have run
five simulation models following the simulation proce-
dures described in Materials and Methods. Treatment
effects on the signal were varied between 0.5 (very small)
and 2.5 (very large) in the five models. To compare per-
formance, we used Summarized Receiver Operating Char-
acteristic (SROC) curves, where the test sensitivities and
specificities (true positive and true negative proportions)
for a range of p-value cutoffs (or FDR cutoffs for results
with multiple testing adjustments) were averaged over
100 simulated datasets. Figures 1 and 2 show SROC
curves of models 2 and 4, where large and small treatment
effect sizes, respectively, were chosen in the generated
models.
The SROC curve's overall behavior can be measured by
the Area Under the Curve (AUC) [19]. Table 2 shows
AUCs for five simulation models under different weight-
ing and multiple testing strategies. As seen from the table
and figures, weighted t-statistics based on quality measure
, in which a gene was excluded if one or more arrays
have an absent call, had the lowest AUC in all models.
Whether p-values were unadjusted or adjusted by the
weighted Benjamini-Hochberg (WBH) method, 
outperformed the other quality scores in models 1, 2, and
3, where a moderate to large treatment effect was chosen.
Although   had the overall best performance for
models 4 and 5, where a small treatment effect was used,
 has the best sensitivity when specificity is larger
than 95% (shown in Figure 2). We also observed that
 had similar performance to   for models 1, 2
and 3, but   outperformed   for models 4 and 5.
 has slightly worse performance than   for mod-
els 1,2 and 3, but their performance is almost the same for
models 4 and 5; conversely, the statistic   performed
better, relative to the other methods, for small effect sizes.
The performance of no filtering at all,  , was also a good
choice for small changes in gene expression. Therefore,
the best choice of weighting statistic in the presence of
adjustments for multiple testing appears to depend on the
size of the treatment effects. We also found that it is better
to define quality measures directly from Affymetrix detec-
tion p-values rather than from the Affymetrix Present/
Marginal/Absent calls.
Qg
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Duchenne muscular dystrophy vs. normal muscle
Haslett et al. [16] compared gene expression between 12
quadriceps biopsies from Duchenne muscular dystrophy
(DMD) patients and 12 quadriceps biopsies of normal
skeletal muscle. Using a method called geometric fold
change (GFC), they identified 133 differentially expressed
genes (139 probesets) with a permutation-based false dis-
covery rate of 2.3 × 10-3; Of these, 12 genes (13 probesets)
were confirmed by RT-PCR. This set will be referred to as
the "RT-PCR" probesets.
Tables 3 and 4 compare the agreement between probesets
selected by our test statistics and Haslett et al. [16]. In
Table 3, for each test statistic, we selected the top T = 30,
50, 100 or 139 significantly expressed probesets, ranked
based on our adjusted false discovery rates, and we
counted the number of these probesets that were also in
the top T probesets identified by GFC and ranked based
on their absolute fold changes. Table 4 shows a similar
comparison for the RT-PCR set.
The measure   had the worst performance in concord-
ance for the lists of top T probesets in Table 3, and for
identifying RT-PCR probesets in Table 4. The weighted t-
statistics based on   and   performed quite simi-
larly, and gave results that were close also to three other
statistics ( ), but   showed slightly bet-
ter results in Table 3 than these other methods. Interest-
ingly, the FDR values in Table 3 associated with   are
visibly larger than for the other methods. Although there
is more agreement between GFC and   in Table 3
than for other methods when the number of selected
probesets is small (< = 100), the agreement decreases
when more probesets are selected, even though the FDR
estimates are smaller. This statistic is obviously very differ-
ent from the others. When examining Table 3 for T = 30,
agreement for all methods with the GFC paper was
slightly better using MAS5. This may not be surprising
since Haslett et al. [16] used MAS5 also, although, in
Table 3, this relationship not entirely consistent across dif-
ferent values of T. In Table 4, however, the agreement is
always better using MAS5.
Analysis of Choe's spiked-in data
The availability of data from spiked-in experiments (Choe
et al. [17]) provides an excellent opportunity to examine
the performance of our weighted statistics on real data
where the answers are known. Selected transcripts were
added at a range of known concentrations; some were
chosen to have differential expression between two
groups of samples (true positive changes in expression);
others were spiked-in at the same concentration in the
two groups (true negative changes in expression).
Qg
call
Qg
exp Qg
beta
Qg
0 Qg
meanp Qg
we Qg
exp
Qg
exp
Qg
LPE
Receiver Operator Characteristic (ROC) plots for tests of  differential expression in the simulated data with treatment  effect δg = 2.0 Figure 1
Receiver Operator Characteristic (ROC) plots for tests of 
differential expression in the simulated data with treatment 
effect δg = 2.0. Six weighted tests and the local pooled error 
(LPE) test are compared. (a) p-values unadjusted for multiple 
testing, (b) p-values adjusted by the weighted Benjamini and 
Hochberg (WBH) multiple testing method.
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Figures 3 and 4 show the ROC curves for the comparison
of the two groups for MAS5 and RMA, respectively. Table
5 shows the AUC under different weighting and multiple
testing strategies. For both the RMA and MAS5 strategies,
it is still clear that whether p-values were unadjusted or
adjusted by the WBH method,   outperforms the
other quality scores. However, unlike the results in the
DMD as well as the simulated data, here the quality meas-
ure   had better performance than  ,   and
. In general, the results based on the MAS5 strategy
are slightly better than those based on RMA for any qual-
ity-based test statistic, but the relative rankings of the dif-
ferent statistics remain almost the same across the two
summarization methods. The LPE test appears to be par-
ticularly sensitive to the summarization method. It per-
forms very well for the MAS5 method without multiple
testing corrections and very poorly when the BH multiple
testing is used. Test statistics based on   and 
had better performance than the LPE test when p-values
were adjusted by the WBH in both MAS5 and RMA.
Discussion
In traditional gene selection methods, pre-filtering and
selection are two separate procedures, and commonly
used pre-filtering methods are based on Affymetrix calls
[6-9]. We unified gene filtering and gene selection proce-
dures together, where the importance of a gene is meas-
ured by its quality score, defined across all arrays and
experimental groups, rather than by a given cutoff call
value. The methods, therefore, overcome the shortcom-
ings of the traditional methods to filter out genes before
any high-level data analysis, such as gene selection, is car-
ried out.
Our measure   is essentially the same as the tradi-
tional method of keeping only probesets where all arrays
record a present call. Our results clearly demonstrated that
the weighted t-statistic based on   has the worst per-
formance in the real data and all simulation models;
Pounds and Cheng [11] also found that simple filtering
based on Present/Marginal/Absent calls was a poor
choice. However, this statistic performed well in the
spiked-in data. This artificially-created dataset contained
only transcripts that were added in known concentrations,
therefore the expression signals are likely to be much
more consistent across arrays than signals from different
individuals.
The best choice of weighting statistic in the presence of
adjustments for multiple testing appears to depend on the
size of the treatment effects. The exponential model meas-
Qg
exp
Qg
call Qg
0 Qg
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Qg
we
Qg
exp Qg
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Qg
call
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Receiver Operator Characteristic (ROC) plots for tests of  differential expression in the simulated data with treatment  effect δg = 1.0 Figure 2
Receiver Operator Characteristic (ROC) plots for tests of 
differential expression in the simulated data with treatment 
effect δg = 1.0. (a) p-values unadjusted for multiple testing, 
(b) p-values adjusted by the weighted Benjamini and Hoch-
berg (WBH) multiple testing method.
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ure,  , appears to have a slight advantage over the
one-parameter beta distribution  , although for small
effect sizes they perform very similarly. The distribution of
quality scores for the exponential model gives, in general,
lower weight to probesets with small detection p-values
than the beta distribution. This may lead to a small reduc-
tion in sensitivity – the effect of these lower weights can
be seen when examining the FDR cutoffs in the DMD
data, and in the figures. However, these lower weights also
improve specificity which tends to lead to better overall
prediction.
For quality measures   and  , the performance of
the weight depends on the sensitivity parameter ν. In
order to analyze the effect of different values of parameter
ν on our results, we did another simulation study. Table 6
summarizes the sensitivity and specificity of the proposed
test procedures to detect differentially expressed genes
(using the weighted Benjamini-Hochberg procedure to
control the false discovery rate at 5%), as a function of ν
when the treatment effect was set to 2.0. The sensitivity
decreases and specificity increases as ν gets smaller. The
sensitivity associated with   is slightly better than
 across this table, but the specificity is worse. It can
be argued that the optimal choice of ν is the one that
comes closest to perfect prediction. For ν = 0.05 and 0.01,
the Euclidean distances from the point where sensitivity =
1 and specificity = 1 are 0.153 and 0.157, for the exponen-
tial distribution, and 0.219 and 0.221, for the beta distri-
bution, respectively. Therefore, we fixed ν = 0.05 in our
analysis; this choice can be thought of as a p-value of 0.05,
leading to the interpretation that a representative tran-
script from a particular experimental group will be called
present when the expected (under the assumed distribu-
tion) p-value <0.05. In fact, the significance level of 0.05
is widely used in statistical hypothesis testing and is com-
parable to the thresholds for Present/Marginal/Absent
calls used in the Affymetrix software.
It is now a common practice to use procedures for control-
ling multiple testing when identifying differentially
expressed genes. Various procedures, such as the Bonfer-
roni correction, the Benjamini and Hochberg false discov-
ery rate [4], or the Benjamini and Yekutieli false discovery
rate [20], have been widely used. Due to the quality
adjustment in our proposed t-statistics, we can no longer
assume that the p-values ptg have a uniform distribution
under the null hypothesis, and we can not assume that the
test statistics have identical distributions. Therefore, we
developed weighted multiple testing procedures. Our
findings showed that the proposed weighted Benjamini
and Hochberg (WBH) adjustment procedure is better
than the weighted Bonferroni (WB) and weighted Ben-
jamini and Yekutieli (WBY) adjustment procedures
(results not shown). However, we also observed that the
proposed t-statistics using WB and WBY had poor sensitiv-
ity, regardless of the type of quality measure score (data
not shown). We are planning to further extend weighted
multiple testing methods in order to redefine Storey and
Tibshirani's positive false discovery rate (pFDR) [21],
Qg
exp
Qg
beta
Qg
exp Qg
beta
Qg
beta
Qg
exp
Table 2: Area under the curves (AUCs) for five simulation models *
Model Multiple 
Testing
Quality Measures
Model 1 δg = 2.5 Unadjusted 0.777 0.380 0.925 0.892 0.871 0.743 0.924
WBH 0.812 0.382 0.929 0.895 0.885 0.772 0.932
Model 2 δg = 2.0 Unadjusted 0.840 0.387 0.934 0.907 0.898 0.809 0.932
WBH 0.878 0.387 0.937 0.912 0.911 0.846 0.937
Model 3 δg = 1.5 Unadjusted 0.895 0.394 0.933 0.918 0.922 0.868 0.932
WBH 0.925 0.395 0.937 0.923 0.932 0.902 0.936
Model 4 δg = 1.0 Unadjusted 0.918 0.399 0.921 0.913 0.926 0.889 0.915
WBH 0.935 0.401 0.917 0.918 0.934 0.912 0.891
Model 5 δg = 0.5 Unadjusted 0.876 0.408 0.875 0.876 0.884 0.850 0.850
WBH 0.882 0.410 0.858 0.861 0.882 0.860 0.770
For   and  , the sensitivity parameter ν was set to 0.05.
* Simulated probe level data was summarized using RMA
Qg
0 Qg
call Qg
exp Qg
beta Qg
meanp Qg
we Qg
LPE
Qg
exp Qg
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where the test statistics are assumed to be identically dis-
tributed.
Several other modified t-statistics, such as SAM [22],
penalized t-statistics [23], or the local pooled error
method used here [18], have been developed for microar-
ray data analysis. All of these methods focus on overcom-
ing the shortcoming of the ordinary t-statistics for ranking
genes, due to unstable variance estimates that may arise
when sample size is small. Each method used a slightly
different strategy to estimate a penalty parameter for
smoothing unstable variance estimates, using informa-
tion from all genes rather than relying solely on variance
estimates from an individual gene. However, as we dis-
cussed in the "Background" Section, the quality of this
information is not the same across genes. Therefore, the
estimate of the penalty parameter may not be reliable if
we assume that all gene-specific information has the same
quality. Here, we take another strategy to improve the per-
formance of ordinary t statistics by putting a high weight
for the genes with high quality and a low weight for those
with low quality in the t-statistic calculations. The initial
comparison of our strategy with the LPE test demon-
strated that our weighted tests based on   and 
are promising – AUC results were fairly similar, and better
in several cases. Although our weighting strategy could be
combined with a revised variance-smoothing algorithm
to potentially improve the performance of the test statis-
tics in small samples, this was not the focus of this work.
It should be noted that the probe-level data analysis (such
as background correction, normalization and summariza-
tion methods) may influence the results of the test proce-
dures we discussed. Our initial analysis of real data and
spiked-in data show that the weighted test statistics based
on the MAS5 strategy may have slightly better perform-
ance than those based on the RMA strategy. In future
investigations, we plan to explore how different probe-
level data analysis methods, such as MAS5, dCHIP, RMA,
PLIER and gcRMA, and different detection p-value calcu-
lation methods [17], may influence our weighting strategy
in detail.
Our results showed that some true differences are missed
with any filtering method, as was noted by others [11]. It
is known that the mismatch probes measure some true
signal [12], and therefore is possible that, especially for
genes expressed at a low level, quality scores for real data
are lower than in our simulated data. Defining an alterna-
tive to the detection p-value that does not depend on the
mismatch data may lead to better sensitivity. However, if
mismatch probes do contain signal, and a study wishes to
identify small changes in gene expression, the decision to
use any filter at all must be carefully considered, given that
some true effects are likely to be excluded. In addition,
when effects are small, it must be realized that using mul-
tiple testing corrections will also lead to the exclusion of
real effects.
Qg
exp Qg
beta
Table 3: Agreement in probeset selections between our methods and Haslett et al. [16]: Given a chosen number of selected probesets, 
how many of the probesets selected by GFC were also selected by the methods in this paper (corresponding false discovery rate 
WBH-FDR)
Summarizatio
n Method
Number of 
probesets 
selected
MAS5 30a 10b (3.6e-06c) 6 (7.6e-06) 10 (6.2e-04) 10 (4.9e-06) 10 (3.6e-06) 11 (3.6e-06) 17 (2.3e-21)
50 21 (1.4e-05) 13 (1.6e-05) 25 (2.3e-03) 22 (1.0e-05) 21 (1.2e-05) 22 (7.8e-06) 32 (6.0e-13)
100 56 (3.5e-05) 40 (1.5e-04) 59 (4.1e-03) 57 (2.2e-05) 56 (2.6e-05) 56 (1.9e-05) 61 (3.3e-09)
139 (2.3e-03) 94 (1.1e-04) 65 (3.3e-04) 96 (9.2e-03) 95 (8.4e-05) 94 (9.3e-05) 94 (6.1e-05) 76 (4.1e-07)
RMA 30 8d (1.3e-05) 7 (2.5e-05) 9 (1.9e-03) 8 (7.5e-06) 8 (9.7e-06) 8 (5.6e-06) 20 (1.8e-18)
50 24 (4.3e-05) 13 (5.0e-05) 26 (3.4e-03) 24 (2.8e-05) 24 (3.2e-05) 24 (2.0e-05) 30 (1.8e-11)
100 60 (1.4e-04) 42 (3.3e-04) 63 (1.1e-02) 60 (9.8e-05) 60 (1.3e-04) 59 (8.0e-05) 62 (3.5e-07)
139 85 (2.5e-04) 69 (7.4e-04) 92 (1.9e-02) 92 (2.0e-04) 89 (2.2e-04) 85 (1.5e-04) 77 (2.2e-05)
a The top 30 probesets were selected by each method.
b 10 probesets overlapped between the top 30 probesets selected by GFC and the top 30 probesets selected by  , when data were summarized 
using MAS5.
c The WBH-FDR for the top 30 probesets selected by   was 3.6e-06.
d 8 probesets overlapped between the top 30 probesets selected by GFC (data normalized by MAS5) and the top 30 probesets selected by   
(data normalized by RMA).
e Sensitivity parameter ν = 0.05.
Qg
0 Qg
call Qg
expe Qg
betae Qg
meanp Qg
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The proposed quality measures may also be useful in
other applications of microarray experiments. For exam-
ple, in microarray meta-analysis we could weight based
on not just the quality of a study [24], but the quality of
each measurement [25,26].
Methods
Quality measures
The quality of a probeset may depend on many quantities
such as spatial arrangement on arrays, upper and lower
threshold effects, etc. Here we focus on measuring reliabil-
ity and consistency of a probeset's expression using the
probeset's detection p-value. The distribution of expres-
sion within a probeset, leading to a detection p-value, is
influenced by all stages of the microarray process includ-
ing scanner brightness, background, RNA quality, chip
design, etc. [5]. Therefore, it can be thought as a synthesis
index to represent the probeset's quality.
In this paper, we defined quality measures hierarchically
at 3 levels (Table 1): (a) gene and array level, (b) gene and
group level, summarizing across arrays within each group,
(c) gene level, summarizing across arrays as well as
groups. Suppose there are i = 1, 2, ..., I arrays in total, each
containing g = 1, 2, ..., G genes. Further, assume that there
are W treatment groups, each consisting of nw arrays, for w
= 1, 2, ..., W. Therefore, for the first aspect (a), we meas-
ured the quality of the measure of expression for one tran-
script based on the detection p-value or the Affymetrix
Present/Absent/Marginal call [5]. Two measures were
defined, which we denote by qgi, the detection p-value,
and  , based on the present/absent call (see Table 1).
Approaches for summarizing across a set of arrays take
two forms. Firstly, the quality of a gene's measurement
across a particular group of arrays can be defined; we call
this  . Several different quality scores are described in
Table 1, with more detail below for the exponential and
beta distributions. Secondly, group-level quality scores
can be used to create a single summary measure that
applies to all arrays being analyzed. For the latter, we use
Qg = maxw∈{1 ...W}[ ] . Use of the maximum leads to the
desirable property that genes present under one set of
experimental conditions but absent under another will be
retained for analysis with a high quality score.
To develop a model-based quality measure, we argued as
follows: if a gene is not expressed or cannot be measured,
then the detection p-values (qgi) are expected to follow a
uniform distribution. Equivalently, if a gene's expression
cannot be detected, then we can assume a common distri-
bution for this gene for all arrays in group w, such that -
log(qgi) ~ Exp(1). That is, the negative log(qgi) follows an
exponential distribution with a rate parameter value of 1
[25]. We therefore made the assumption that the qgi for
gene g and array i follows the one-parameter exponential
distribution with a group specific mean λgw, w = 1, ..., W,
qgi
*
Rg
w
Rg
w
Table 4: Comparison of our methods and Haslett et al. [16]. Identification of differentially-expressed probesets validated by RT-PCR: 
given a chosen number of probesets selected by GFC, and the number of probesets validated by RT-PCR within this set, how many of 
the RT-PCR probesets were selected by the methods in this paper.
Method # of probesets selected: 
# of GFC selections validated by RT-PCR
MAS5 30a : 8b 5c 15 5 5 5 4
50 : 11 8 2 7 7 8 7 6
100 : 12 11 3 10 10 11 10 11
139 : 13 12 4 11 11 12 12 12
RMA 30 : N/A 2d 14 2 2 2 6
50 : N/A 6 2 7 6 6 6 7
100 : N/A 9 4 9 9 9 8 8
139 : N/A 10 4 11 10 10 10 11
a The top 30 probesets were selected by each method.
b 8 probesets in the top 30 were validated by RT-PCR in Haslett et al. [16].
c 5 RT-PCR probesets were among the top 30 probesets selected by  . The 5 RT-PCR probesets are among the 8 RT-PCR probesets selected 
by GFC.
d 2 RT-PCR probesets were among the top 30 probesets selected by   (data normalized by RMA). The 2 RT-PCR probesets are among the 8 
RT-PCR probesets selected by GFC, using the MAS5 normalization.
e Sensitivity parameter ν = 0.05.
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so that -log(qgi) ~ Exp(λgw). The maximum likelihood esti-
mate of λgw is the inverse of the group-specific sample
mean. Define ν, a sensitivity parameter, to be a desired
threshold for the detection p-values, representing 1 minus
the probability that any probeset in a particular treatment
group shows a detectable signal. Then P(qgiw ≤ ν) leads to
. Although the
distribution of the qgi may not follow an exponential dis-
tribution exactly, this simple assumption may give ade-
quate results for developing quality measures.
Theoretically, p-values are expected to follow a two-
parameter Beta distribution. However, estimating these
two parameters is occasionally impossible due to the fact
that the detection p-values are derived from rank tests,
and all arrays may have exactly the same p-value when
genes are highly expressed. Pounds and Cheng [11]
recently proposed a one-parameter Beta distribution to
model detection p-values within each experimental
group, ,  with
sensitivity parameter ν. The parameter   can be esti-
mated by  [27], where
Tests of differential expression with quality weights
In traditional meta-analysis, quality measures are often
used when combining results from different studies [28].
Without loss of generality, we can assume that we are
comparing two groups of microarrays (with NA arrays in
group A and NB in group B), and testing for differentially-
expressed genes with the two-sample Welch t-statistic, not
assuming equal variances. For gene g, the test statistic is
therefore  , where   and 
denote the sample average intensities in groups A and B,
respectively, and   and   denote the corresponding
sample variances. For more than two groups, an F statistic
could be used instead. The quality measure (Qg) for gene
g is then incorporated by   = tgQg. Therefore,   = tg when
Qg = 1, and   goes to zero with low quality scores.
We converted this modified t-test statistic to a p-value by
reference to a standard t-distribution with degrees of free-
dom based on Satterthwaite's approximation [29], assum-
ing unequal variances between groups A and B. Of course,
it is clear that   will no longer follow the t-distribution,
since the kurtosis will be substantially altered as Qg gets
closer to zero. However, the next section describes how
these altered p-values were used in modified adjustments
for multiple testing.
This simple approach of weighting the t-test statistics can
be contrasted with the approach of weighting the expres-
sion intensities within the test statistic. Using standard
formula for weighting based on quality, we constructed
, where   and   are
the group-specific weighted means and standard devia-
tions [30], weighted by 1 - qqi. Here, w = A, B. We obtained
pqtg from a t-distribution with degrees of freedom based on
Satterthwaite's approximation [29]. For brevity, we refer
to this approach as   even though there was no specific
quality measure attached to each gene.
RP q e g
w
giw
gw =− ≥ − = ( log( ) log )
log ν
λν
Rp q B e t a q a d q g
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agw =≤ = = ∫ ()( ; ) νν
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0
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ˆ /( ) aq q gw gw gw =− 1
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t
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gA gB
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*
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Table 5: Area under the curves (AUCs) of Choe's spiked-in data (ν = 0.05)
Method Multiple 
Testing
Quality Measures
RMA Unadjust 0.800 0.881 0.885 0.882 0.850 0804 0.854
WBH 0.779 0.871 0.874 0.868 0.832 0.776 0.847
MAS5 Unadjust 0.815 0.889 0.901 0.896 0.869 0.814 0.922
WBH 0.800 0.877 0.895 0.884 0.856 0.789 0.653
Qg
0 Qg
call Qg
exp Qg
beta Qg
meanp Qg
we Qg
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Multiple hypotheses testing with weights
Several authors have considered the problem of including
weights in multiple hypothesis testing situations [31-33].
Often, weights have been introduced when some of the
hypotheses Hi are deemed more important than others.
For example, Holm [31] first introduced weights into his
sequentially rejective multiple hypothesis testing proce-
dure, where weight was used to indicate the importance of
the hypotheses. In that spirit, testing for differences in
genes that are not expressed or non-specific in such genes
should be considered less important than testing for dif-
ferences among genes that are specific and well-expressed.
To give another perspective, our quality-weighted statis-
tics t* can also be considered as an implementation of a
filtering method. For example,   is a straightforward
implementation of filtering based on including only
genes with present calls on all arrays, and our other meas-
ures effectively exclude genes with small quality measures
when the weighted statistic t* is close to zero. Therefore,
we propose to adjust the effective number of genes tested
to correspond to the number of tested genes of high qual-
ity.
Assume that quality measures Q1, Q2, ..., QG and signifi-
cance values p1, p2, ..., pG have been calculated for all G
genes. Let   denote the ordered signifi-
cance values, and let   denote the quality
measures in the same order. We redefined the Benjamini
and Hochberg (BH) multiple testing procedure as
. The sums of the
quality measures in this formula estimate the number of
high quality genes instead of the number of genes. We call
this approach the Weighted Benjamini and Hochberg
(WBH) method. Similar modifications lead to a weighted
Benjamini and Yekutieli (WBY) procedure (not shown).
We applied WBH to the t-statistics modified by the quality
measures  ,  ,   and  . For the t-statis-
tics modified by quality measures   and   as well as
local pooled error (LPE) test  , the standard form of
the Benjamini and Hochberg (BH) multiple testing proce-
dure was used.
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Receiver Operator Characteristic (ROC) plots for tests of  differential expression in Choe's spiked-in data summarized  by MAS5 Figure 3
Receiver Operator Characteristic (ROC) plots for tests of 
differential expression in Choe's spiked-in data summarized 
by MAS5. (a) p-values unadjusted for multiple testing, (b) p-
values adjusted by the weighted Benjamini and Hochberg 
(WBH) multiple testing method.
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Simulation method
Affymetrix probe level data were generated based on a
unified model proposed by Wu et al. [14]. When treat-
ment effects are considered for different conditions, such
as cancer and normal tissues, gene expression across these
conditions can be modeled as:
where Ygij and Wgij are the PM and MM intensities for the
probe j in probeset g on array i respectively; O denotes
optical noise. N  represents non-specific binding (NSB)
noise. S is a quantity proportional to RNA expression and
the coefficient 0 < Φ < 1 accounts for the fact that for some
probe-pairs the MM detects signal. Following Wu et al.
[14], we simulated   and   using independent
draws from log2()  ~  N(5, 0.1) and log2()  ~
N(5, 0.1). We set   =   = 4.6, and assumed that
 and   follow a bivariate normal distribution
with mean 0, variance 1, and correlation 0.88. We then
generated identically and independently distributed ran-
dom variates e ~ N(0,0.08), so that   and
similarly  . When mismatch probe j of
gene g is attached by picking up stray signal, Φgi is gener-
ated as Φgi ~ Beta(0.5,5), otherwise, Φgi = 0. The propor-
tion of attached probes among total probes was set to
0.01. Since S follows a power law, we set its base to 2.
Therefore, if we denote γg as the baseline log expression
level for probeset g, we can select log2(γg) expression levels
from 0 to 12, which were generated from γg  ~ 12*
Beta(1,3) + 1. δg is the expected differential expression of
gene g across different conditions, which is varied in the
simulations. bi, which describes the need for normaliza-
tion, was set to be zero. αgij is the signal detecting ability
of probe j in gene g on array i, which is assumed to follow
a normal distribution with mean zero and signal detec-
tion variance  . Multiplicative errors   and 
were generated independently from N(0,  ). Values of
 and   were varied in the simulations. Since the the-
oretical maximum value of an Affymetrix scanner is 216,
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Receiver Operator Characteristic (ROC) plots for tests of  differential expression in Choe's spiked-in data was summa- rized by RMA Figure 4
Receiver Operator Characteristic (ROC) plots for tests of 
differential expression in Choe's spiked-in data was summa-
rized by RMA. (a) p-values unadjusted for multiple testing, (b) 
p-values adjusted by the weighted Benjamini and Hochberg 
(WBH) multiple testing method.
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we kept only generated Ygij and Wgij less than 216, that is,
 and
. The RMA algo-
rithm [12] was used to summarize simulated probe-level
data into a signal value, and the MAS5 algorithm [5] was
used to obtain the detection p-value.
Design of simulation study
The simulation design is shown in Table 7. We assumed
two groups, A and B, with NA and NB arrays, respectively.
G  genes were generated, of them the proportion of
expressed genes is k, and the proportion of differentially
expressed genes is d of the G*k expressed genes. We set the
number of up-and -down regulated genes to be the same
in this study. Therefore, the G genes are divided into four
groups: a non-expressed gene group where genes are not
expressed across all arrays in group A and group B; a non-
differentially expressed gene group where genes are
expressed but not differentially between groups A and B;
an up-regulated gene group where the mean gene expres-
sion of gene g in group B is larger by δg than that in group
A; and a down-regulated gene group where the mean gene
expression of gene g in group A is larger by δg than that in
group B.
We ran five simulation models following the above
design. The specific parameters used in the five models
are: number of genes: 1000; sample size: 25 arrays in
groups A and B, respectively (for a total of 50 arrays);
number of probes within each probeset: 16; proportion of
YO N S gij gij
PM
gij
PM
gij
PM =+ + min( , ) 216
WO N S gij gij
MM
gij
MM
gij
MM =+ + min( , ) Φ 216
Table 7: Simulation structure of Affymetrix microarray data
Group A Group B
Array 1 ...... Array NA Array 1 ...... Array NB
Up-regulated 
Gene Group
g1 γg γg = γg + δg
...
gd*k*G/2
Down-
regulated Gene 
Group
gd*k*G/2+1 γg = γg + δg γg
...
gd*k*G
Non-
differentially 
Expressed Gene 
Group
gd*k*G+1 γg ≠ 0 
δg = 0
...
gk*G
Non- Expressed 
Gene Group
gk*G+1 γg = 0
δg = 0
...
G
Table 6: Sensitivity and specificity for detecting differentially expressed genes, as a function of the sensitivity parameter ν
ν
Sensitivity Specificity Sensitivity Specificity
0.6 0.9996 0.7562 0.9998 0.7207
0.5 0.9995 0.7763 0.9997 0.7372
0.4 0.9981 0.7930 0.9994 0.7490
0.3 0.9967 0.8070 0.9990 0.7590
0.2 0.9922 0.8211 0.9984 0.7668
0.1 0.9831 0.8373 0.9956 0.7752
0.05 0.9660 0.8507 0.9936 0.7812
0.01 0.9167 0.8665 0.9413 0.7873
Qg
exp Qg
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expressed genes: 0.5; proportion of differentially
expressed genes: 0.1; signal detection variance: 0.25; mul-
tiplicative error variance: 0.05 and sensitivity parameter ν:
0.05.
Duchenne muscular dystrophy data
Haslett et al. [16] hybridized the total RNA to HG-U95Av2
GeneChips. They used MAS5 to obtain signal intensities
and normalized with a linear regression. Tests of differen-
tial expression were based on geometric fold change
(GFC) [16]. The differential expression of 12 genes (13
probesets) was confirmed by quantitative RT-PCR analysis
of seven DMD biopsies and four unaffected biopsies. We
used only 23 arrays (only 11 DMD arrays) for our re-anal-
ysis since one file was truncated. Raw data were converted
to signal estimates using both MAS5 [5] and RMA [12],
both were implemented using the affy package in Biocon-
ductor [34].
Spiked-in data of Choe et al. [17]
The 'spiked-in' experiment (Choe et al. [17]) for Affyme-
trix Genechips provides a controlled dataset of 3,860 RNA
species with known sequence and known concentration.
Two different samples were prepared and hybridized in
triplicate to Affymetric GeneChips; these are called the
'constant' (C) and 'spike' (S) samples. Out of 3,860 RNA
species, 2,551 of them were created to have the same con-
centrations in both samples while the rest (1,309) were
spiked in with different concentrations between the S and
C samples. Ten fold-change levels, ranging from 1.2 to 4-
fold, were assigned to the spiked-in RNAs. Basically, all
the RNAs with positive log fold changes can be thought of
as differentially expressed genes. In this study, we consid-
ered the top 1000 probesets as differentially expressed
genes (as did Choe et al. [17]).
Authors' contributions
CG initiated, designed and managed the study. CG also
proposed the methods in this manuscript. JB participated
in designing and managing the study. PH conducted data
analysis and drafted the manuscript. CG and JB revised
the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We acknowledge helpful suggestions from two anonymous reviewers that 
greatly improved the quality of the manuscript. This work was supported 
by the Ontario Genomics Institute and Genome Canada.
References
1. Su AI, Cooke MP, Keith AC, Yaron H, John RW, Tim W, Anthony PO,
Raquel GV, Lisa MS, Aziz M, Ardem P, Garret MH, Peter GS, John BH:
Large-scale analysis of the human and mouse transcrip-
tomes.  Proceedings of the National Academy of Sciences USA 2002,
99:4465-4470.
2. Affymetrix-Human Genome Arrays   [http://www.affyme
trix.com/support/technical/datasheets/human_datasheet.pdf]
3. Ge Y, Dudoit S, Speed TP: Resampling-based multiple testing
for microarray data hypothesis.  Test 2003, 12:1-44.
4. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a
practical and powerful approach to multiple testing.  Journal of
the Royal Statistical Society B 1995, 85:289-300.
5. Affymetrix – Statistical Algorithms Description Document
[http://www.affymetrix.com/support/technical/whitepapers/
sadd_whitepaper.pdf]
6. Hittel DS, Kraus WE, Hoffman EP: Skeletal muscle dictates the
fibrinolytic state after exercise training in overweight men
with characteristics of metabolic syndrome.  Journal of Physiol-
ogy 2003, 548:401-410.
7. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC,
Landfield PW: Gene microarrays in hippocampal aging: statis-
tical profiling identifies novel processes correlated with cog-
nitive impairment.  The Journal of Neuroscience 2003,
23:3807-3819.
8. Chen YW, Nader G, Baar KR, Hoffman EP, Esser KA: Response of
rat muscle to acute resistance exercise defined by transcrip-
tional and translational profiling.  Journal of Physiology 2002,
545:27-41.
9. Li C, Wong WH: DNA-Chip Analyzer (dChip): user manual.
[http://biosun1.harvard.edu/complab/dchip/filter_gene.htm].
10. Li C, Wong W: Model-based analysis of oligonucleodide array:
Expression index computation and outlier detection.  Proceed-
ings of the National Academy of Sciences USA 2001, 98:31-36.
11. Pounds S, Cheng C: Statistical development and evaluation of
microarray gene expression data filters.  Journal of Computa-
tional Biology 2005, 12:482-495.
12. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP:
Summaries of Affymetrix genechip probe level data.  Nucleic
Acids Research 2003, 31:e15.
13. Affymetrix – Technical Manual   [http://www.affymetrix.com/
support/technical/manual/expression_manual.affx]
14. Wu Z, Irizarry RA, Gentleman R, Martinez MF, Spencer F: A Model
Based Background Adjustement for Oligonucleotide Expres-
sion Arrays.  Journal of the American Statistical Association 2004,
99:909-915.
15. Seo J, Bakay M, Chen Y, Hilmer S, Sheneiderman B, Hoffman EP:
Optimizing signal/noise ratios in expression profiling:
Project-specific algorithm selection and detection p value
weighting in Affymetrix microarrays.  Bioinformatics 2004,
20:2534-2544.
16. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane
IS, Beggs AH, Kunkel LM: Gene expression comparison of biop-
sies from Duchenne muscular dystrophy (DMD) and normal
skeletal muscle.  Proceedings of the National Academy of Sciences USA
2002, 99:15000-15005.
17. Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS: Pre-
ferred analysis methods for Affymetrix GeneChips revealed
by a wholly defined control dataset.  Genome Biology 2002, 6:R16.
18. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK: Local-
pooled-error test for indentifying differentially expressed
genes with a small number of replicated microarrays.  Bioin-
formatics 2003, 19:1945-1951.
19. Hanley JA, McNeil BJ: The meaning and use of the area under a
receiver operating characteristic (ROC) curve.  Radiology
1982, 143:29-36.
20. Yekutieli D, Benjamini Y: Resampling-based false discovery rate
controlling multiple test procedures for correlated test sta-
tistics.  Journal of Statistical Planning and Inference 1999, 82:171-196.
21. Storey JD, Tibshirani R: Statistical significance for genome-wide
studies.  Proceedings of the National Academy of Sciences USA 2003,
100:9440-9445.
22. Tusher V, Tibshirani R, Chu G: Significance analysis of microar-
rays applied to the ionizing radiation response.  Proceedings of
the National Academy of Sciences USA 2001, 98:5116-5121.
23. Smyth GK: Linear models and empirical Bayes methods for
assessing differential expression in microarray experiments.
Statistical Applications in Genetics and Molecular Biology 2004, 1:Article
3.
24. Choi JK, Yu U, Kim S, Yoo OJ: Combining multiple microarray
studies and modeling inter-study variation.  Bioinformatics 2003,
19:i84-i90.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2006, 7:33 http://www.biomedcentral.com/1471-2164/7/33
Page 15 of 15
(page number not for citation purposes)
25. Hu P, Greenwood MTC, Beyene J: Integrative analysis of multi-
ple gene expression profiles with quality-adjusted effect size
models.  BMC Bioinformatics 2005, 6:128.
26. Tritchler D: Modelling study quality in meta-analysis.  Statistics
in Medicine 1999, 18:2135-2145.
27. Lehman EL: Theory of point estimation.  Wiley 1983.
28. Fleiss JL, Gross AJ: Meta-analysis in epidemiology, with special
reference to studies of the association between environmen-
tal tobacco smoke and lunc cancer: a critique.  Journal of Clinical
Epidemiology 1991, 44:127-139.
29. Satterthwaite FW: An approximate distribution of estimates of
variance components.  Biometrics 1946, 2:110-114.
30. SAS Institute Inc. – The MEANS Procedure   [http://
www.caspur.it/risorse/softappl/doc/sas_docs/proc/z0608466.htm]
31. Holm S: A simple sequentially rejective multiple test proce-
dure.  Scandinavian Journal of Statistics 1979, 6:65-70.
32. Benjamini Y, Hochberg Y: Multiple hypotheses testing with
weights.  Scandinavian Journal of Statistics 1997, 24:407-418.
33. Hommel G, Kropf S: Tests for differentiation in gene expres-
sion using a data-driven order or weights for hypotheses.  Bio-
metrical journal 2005, 47:554-562.
34. Gautier L, Cope L, Bolstad BM, Irizarry RA: affy-analysis of
Affymetrix GeneChip data at the probe level.  Bioinformatics
2004, 20:307-315.